Research Activities
ICoN’s research activities are organized into six interconnected work packages (WPs).
WP1 - Unlock potential disease-modifying treatments (DMTs) for clinical testing
Norway has unique access to marine and land-based bioresources, offering strong potential to discover disease-modifying treatments (DMTs). WP1 will unlock this potential by establishing a structured pipeline for identification, validation, and clinical translation.
Read more about WP1 (page under construction).
WP2 - Implement a clinical trial accelerator platform to assess target engagement
SLEIPNIR is an innovative clinical trial platform specifically designed to determine whether potential DMTs penetrate the human brain and engage their intended targets, thereby exerting the desired biological effects. SLEIPNIR, focus of WP2, will evaluate compounds prioritized by WP1.
Read more about WP2 (page under construction).
WP3 - Platform for conducting prodromal clinical interventions
Early intervention offers the best chance to change the course of α-synucleinopathies. WP3 will establish Norway’s first trial platform focused on individuals in the prodromal stage of these devastating neurodegenerative diseases. In partnership with the Mohn Center for Neuroprotection, WP3 will build on the nationwide NOR-RBD cohort of individuals with iRBD - the strongest known predictor of future PD, DLB or MSA. This will position Norway at the forefront of preventive neurotherapeutics.
Read more about WP3 (page under construction).
WP4 - Biomarkers for detection and monitoring of prodromal α-synucleinopathies
Clinical trials are limited by the lack of reliable biomarkers for disease progression and treatment response. In addition, current tools for early diagnosis and monitoring of α-synucleinopathies are resource-intensive and not suited for large-scale use. WP4 will address these challenges by developing and validating biomarker solutions across digital, molecular, and imaging domains.
Read more about WP4 (page under construction).
WP5 - Role of environmental toxicants
Environmental and lifestyle factors, such as diet and exposure to toxicants, are linked to an increased risk of α-synucleinopathies. While current dietary guidelines mainly focus on cardiovascular disease and cancer, neurodegenerative diseases remain largely overlooked. WP5 will explore these links, enabling public health authorities and industry partners to co-develop safer, evidence-based products and recommendations for brain health.
Read more about WP5 (page under construction).
WP6 - Implementation & Valorization of outcomes
WP6 will serve as a collaborative hub connecting ICoN and its partners. It will ensure that scientific discoveries are translated into products, services, policies, and practices that improve health outcomes and create sustainable value for society and industry - while also supporting the continuation of research beyond the center’s 8-year funding period.
Read more about WP6 (page under construction).